Rocket Pharmaceuticals Stock Alpha and Beta Analysis
| RCKT Stock | USD 8.76 0.26 3.06% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rocket Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rocket Pharmaceuticals over a specified time horizon. Remember, high Rocket Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rocket Pharmaceuticals' market risk premium analysis include:
Beta 1.05 | Alpha (0.48) | Risk 3.35 | Sharpe Ratio (0.13) | Expected Return (0.43) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rocket |
Rocket Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rocket Pharmaceuticals market risk premium is the additional return an investor will receive from holding Rocket Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rocket Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rocket Pharmaceuticals' performance over market.| α | -0.48 | β | 1.05 |
Rocket Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rocket Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Rocket Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rocket Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Rocket Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rocket Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rocket Pharmaceuticals stock market price indicators, traders can identify Rocket Pharmaceuticals position entry and exit signals to maximize returns.
Rocket Pharmaceuticals Return and Market Media
The median price of Rocket Pharmaceuticals for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 10.73 with a coefficient of variation of 12.58. The daily time series for the period is distributed with a sample standard deviation of 1.37, arithmetic mean of 10.87, and mean deviation of 1.08. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3 | 12/13/2024 |
2 | Disposition of 896 shares by Militello John of Rocket Pharmaceuticals at 10.38 subject to Rule 16b-3 | 01/23/2025 |
3 | Acquisition by Pratumsuwan Piratip of 22443 shares of Rocket Pharmaceuticals at 10.56 subject to Rule 16b-3 | 02/03/2025 |
4 | Acquisition by Militello John of 29920 shares of Rocket Pharmaceuticals at 9.88 subject to Rule 16b-3 | 02/11/2025 |
5 | Acquisition by Militello John of 20080 shares of Rocket Pharmaceuticals subject to Rule 16b-3 | 02/13/2025 |
6 | RCKT stock touches 52-week low at 9.76 amid market challenges - MSN | 02/14/2025 |
7 | Disposition of 16303 shares by Shah Gaurav of Rocket Pharmaceuticals at 10.58 subject to Rule 16b-3 | 02/21/2025 |
8 | Disposition of 6532 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 10.58 subject to Rule 16b-3 | 02/25/2025 |
9 | Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | 02/27/2025 |
10 | Brokers Offer Predictions for RCKT Q2 Earnings | 03/05/2025 |
11 | Acquisition by Shah Gaurav of 81655 shares of Rocket Pharmaceuticals subject to Rule 16b-3 | 03/13/2025 |
About Rocket Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rocket or other stocks. Alpha measures the amount that position in Rocket Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Rocket Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Rocket Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rocket Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rocket Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rocket Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Rocket Pharmaceuticals' management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rocket Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.